Cơ Chế Tác Dụng :
Actyve hormone therapy employs Vyteris' proprietary Actyve(TM) transdermal drug delivery technology, which is positioned to provide a safe and effective method of delivering drugs via a pre-programmed regulating system that mimics the body's natural rhythms, a characteristic important in the delivery of therapeutics for the treatment of infertility. The Company's Actyve(TM) transdermal technology uses an integrated circuit to control a small amount of current that delivers drugs through the skin. This process is called iontophoresis. The two-component system employs a transdermal patch containing the drug and a small battery-powered controller that precisely controls the rate and amount of drug released from the patch. The level of control is intended to mimic IV or infusion pump delivery without needles.
Vyteris Actyve(TM) transdermal drug delivery technology delivers potentially therapeutic levels of a peptide that is used to treat infertility, in humans. Actyve hormone therapy delivers the peptide for the treatment of female infertility. The peptide could be delivered 24 hours a day in short pulses, to induce ovulation through this technology. The Vyteris smart patch system delivers drug directly to the blood stream, avoiding metabolism by the liver, and reducing the stomach and gastrointestinal upsets that can be associated with oral drug administration. The system is convenient to use and provides a relatively pain free application, avoiding the major drawback of injections and intravenous delivery, and delivers drug doses automatically, minimizing concerns about patient compliance.
Chỉ Định :
Investigated for use/treatment in hormone deficiencies and infertility.